Drug intelligence / Profile preview

esculin + digitalis glycosides + sodium hyaluronate

Development stage: Unknown
Modality: Small Molecules
Administration: Ophthalmic

Overview

This combination medication consists of esculin, digitalis glycosides, and sodium hyaluronate formulated as eye drops. The combination leverages the anti-inflammatory and anti-oxidant properties of esculin and digitalis glycosides, along with the moisturizing and lubricating effects of sodium hyaluronate. Clinical studies have shown this combination to be more effective than either component alone in treating dry eye disease (DED) and other ocular conditions. The medication works by reducing inflammation, providing antioxidant protection, and enhancing moisture retention on the ocular surface.

Other names: EAD combined with 0.3% SHEAD eye drops combined with 0.3% sodium hyaluronate eye drops

Beyond the preview

Go deeper on esculin + digitalis glycosides + sodium hyaluronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on esculin + digitalis glycosides + sodium hyaluronate.

Explore the full profile